Organisation paid for research Program year 2023 Source: CMS Open Payments

Regional Research Specialists

Neither a doctor nor a teaching hospital

Research payments

$300,775

68 payments

Through program year 2023, Regional Research Specialists is reported as receiving $300,775 in research payments, across 68 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$5,554	7
2022	Research	$16,901	8
2021	Research	$92,084	17
2020	Research	$60,780	18
2019	Research	$125,456	18

Breakdown

Who paid Research payments · program years 2019–2023

Dendreon Pharmaceuticals LLC $186,496 47 payments
Cytyc Surgical Products, LLC $56,102 10 payments
Myriad Genetic Laboratories, Inc. $45,700 2 payments
GlaxoSmithKline, LLC. $10,533 7 payments
Spectrum Pharmaceuticals Inc. $1,945 2 payments

Studies the money was for Research payments · program years 2019–2023

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $116,311 15 payments
Penguin $54,437 9 payments
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer $45,700 2 payments
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (Provent) $37,146 13 payments
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $33,038 19 payments
A Phase 3 Study to Compare the Efficacy and Safety of Gepotidacin With $10,533 7 payments
Spi-Qap-306 $1,945 2 payments
Penguin $1,665 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.